Secretaría de Gobernación
CONACYT
INGER
  2. Repositorio Institucional
  3. 1. Artículos
Mi INGER Alertas Editar perfil
Por favor, use este identificador para citar o enlazar este ítem: http://repositorio.inger.gob.mx/jspui/handle/20.500.12100/17263
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.rights.licensehttp://creativecommons.org/licenses/by/4.0es_MX
dc.creatorDAVID HERNANDEZ ALVAREZes_MX
dc.creatorBEATRIZ MENA MONTESes_MX
dc.creatorRAFAEL TOLEDO PEREZes_MX
dc.creatorGIBRAN PEDRAZA VAZQUEZes_MX
dc.creatorSTEFANIE PAOLA LOPEZ CERVANTESes_MX
dc.creatorAlfredo Morales Salazares_MX
dc.creatorEdith Hernández Cruzes_MX
dc.creatorROBERTO CARLOS LAZZARINI LECHUGAes_MX
dc.creatorRoman Royer Vázquez Cárdenases_MX
dc.creatorSilvia Vilchis DeLaRosaes_MX
dc.creatorPEDRO POSADAS RODRIGUEZes_MX
dc.creatorROBERTO SANTIN MARQUEZes_MX
dc.creatorOSCAR ROSAS CARRASCOes_MX
dc.creatorALEJANDRA IBAÑEZ CONTRERASes_MX
dc.creatorADRIANA ALARCON AGUILARes_MX
dc.creatorNORMA EDITH LOPEZ DIAZ GUERREROes_MX
dc.creatorARMANDO LUNA LOPEZes_MX
dc.creatorMINA KONIGSBERG FAINSTEINes_MX
dc.date2019-
dc.date.accessioned2021-10-25T22:05:49Z-
dc.date.available2021-10-25T22:05:49Z-
dc.identifier.urihttp://repositorio.inger.gob.mx/jspui/handle/20.500.12100/17263-
dc.descriptionSarcopenia is a syndrome characterized by a progressive and generalized skeletal muscle mass and strength loss, as well as a poor physical performance, which as strongly been associated with aging. Sedentary lifestyle in the elderly contributes to this condition; however, physical activity improves health, reducing morbidity and mortality. Recent studies have shown that metformin (MTF) can also prevent muscle damage promoting muscular performance. To date, there is great controversy if MTF treatment combined with exercise training improves or nullifies the benefits provided by physical activity. This study is aimed at evaluating the effect of long-term moderate exercise combined with MTF treatment on body composition, strength, redox state, and survival rate during the life of female Wistar rats. In this study, rats performed moderate exercise during 20 of their 24 months of life and were treated with MTF for one year or for 6 months, i.e., from 12 to 24 months old and 18 to 24 months old. The body composition (percentage of fat, bone, and lean mass) was determined using a dual-energy X-ray absorption scanner (DXA), and grip strength was determined using a dynamometer. Likewise, medial and tibial nerve somatosensory evoked potentials were evaluated and the redox state was measured by HPLC, calculating the GSH/GSSG ratio in the gastrocnemius muscle. Our results suggest- that the MTF administration, both in the sedentary and the exercise groups, might activate a mechanism that is directly related to the induction of the hormetic response through the redox state modulation. MTF treatment does not eliminate the beneficial effects of exercise throughout life, and although MTF does not increase muscle mass, it increases longevity.es_MX
dc.formatAdobe PDFes_MX
dc.languageenges_MX
dc.publisherHindawies_MX
dc.relationhttps://www.hindawi.com/journals/omcl/2019/3428543/es_MX
dc.relation.requiresSies_MX
dc.rightsAcceso Abiertoes_MX
dc.sourceOxidative Medicine and Cellular Longevity (1942-0994) Vol. 2019 (2019)es_MX
dc.subjectMEDICINA Y CIENCIAS DE LA SALUDes_MX
dc.subjectCiencias médicases_MX
dc.subjectCiencias clínicases_MX
dc.subjectGeriatríaes_MX
dc.subjectAtrofia musculares_MX
dc.subjectSarcopeniaes_MX
dc.subjectEnvejecimientoes_MX
dc.subjectAginges_MX
dc.subjectEjercicioes_MX
dc.subjectExercisees_MX
dc.subjectLongevidades_MX
dc.subjectLongevityes_MX
dc.titleLong-Term Moderate Exercise Combined with Metformin Treatment Induces an Hormetic Response That Prevents Strength and Muscle Mass Loss in Old Female Wistar Ratses_MX
dc.typeArtículoes_MX
dc.audienceResearcherses_MX
dc.creator.idHEAD811229HDFRLV04es_MX
dc.creator.idMEMB831026MMCNNT03es_MX
dc.creator.idTOPR920725HHGLRF02es_MX
dc.creator.idPEVG910201HHGDZB09es_MX
dc.creator.idLOCS900922MDFPRT08es_MX
dc.creator.idCA1343736es_MX
dc.creator.idCA1343737es_MX
dc.creator.idLALR730123HDFZCB03es_MX
dc.creator.idCA1343738es_MX
dc.creator.idCA1343739es_MX
dc.creator.idPORP870528HMCSDD01es_MX
dc.creator.idSAMR940523HDFNRB09es_MX
dc.creator.idROCO750722HDFSRS05es_MX
dc.creator.idIACA840421MDFBNL00es_MX
dc.creator.idAAAA791115MHGLGD08es_MX
dc.creator.idLODN680314MDFPZR02es_MX
dc.creator.idLULA690630HDFNPR02es_MX
dc.creator.idKOFM650625MDFNNN02es_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercaes_MX
dc.creator.nameIdentifiercaes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercaes_MX
dc.creator.nameIdentifiercaes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
Aparece en las colecciones: 1. Artículos

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Oxidative Medicine and Cellular Longevity (1942-0994) Vol. 2019 (2019).pdf3.05 MBAdobe PDFVisualizar/Abrir
Mostrar el registro sencillo del ítem